On Thursday, Following U.S. Stocks were among the “Top Losers”: Neuralstem, Inc. (NYSEMKT:CUR), ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), Walter Energy, Inc. (NYSE:WLT), Bovie Medical Corporation (NYSEMKT:BVX)
Neuralstem, Inc. (NYSEMKT:CUR), with shares declined -36.63%, closed at $2.37.
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), with shares dropped -22.21%, settled at $34.82.
Walter Energy, Inc. (NYSE:WLT), with shares dipped -19.34%, and closed at $0.460.
Bovie Medical Corporation, (NYSEMKT:BVX), plummeted -16.99%, and closed at $2.59.
Latest NEWS regarding these Stocks are depicted underneath:
Neuralstem, Inc. (NYSEMKT:CUR)
Neuralstem, Inc. (CUR), declared top line data from the Phase II trial of NSI-566 spinal cord-derived neural stem cells under development for the treatment of amyotrophic lateral sclerosis (ALS). The study met primary safety endpoints. The maximum tolerated dose of 16 million transplanted cells and the surgery was well tolerated.
Secondary efficacy endpoints at nine months post-surgery indicate a 47% response rate to the stem cell treatment, as measured by either near-zero slope of decline or positive slope of ALSFRS score in seven out of 15 patients and by either a near-zero decline, or positive strengthening, of grip strength in seven out of 15 patients. Grip strength is an indicator of direct muscle strength of the lower arm. ALSFRS is a standard clinical test used to evaluate the functional status of ALS patients. The average ALSFRS score for responders at 9 months after treatment was 37. Non-responders scored an average of 14. These scores represent 93%, as compared to 35%, of the baseline score retained, respectively, by the responders as compared to non-responders at 9 months, which is a statistically noteworthy difference. As measured by an average slope of decline of ALSFRS, responders’ disease progression was -0.007 point per day, while non-responders’ disease progression was -0.1 per day, which was again statistically significant. Lung function as measured by Seated Vital Capacity shows that responder patients remained within 94% of their starting scores, as compared to 71% for non-responder patients. The trial met its primary safety endpoints. Both the surgery and cells were well-tolerated, with one patient experiencing a surgical serious adverse event.
The open-label, dose-escalating trial treated 15 ambulatory patients, divided into 5 dosing cohorts, at three centers, Emory University Hospital in Atlanta, Georgia, the ALS Clinic at the University of Michigan Health System, in Ann Arbor, Michigan, and Massachusetts General Hospital in Boston, Massachusetts, and under the direction of principal investigator (PI), Eva Feldman, MD, PhD, Director of the A. Alfred Taubman Medical Research Institute and Director of Research of the ALS Clinic at the University of Michigan Health System. Dosing raised from 1 million to 8 million cells in the cervical region of the spinal cord. The final trial cohort also received an additional 8 million cells in the lumbar region of the spinal cord.
The corporation anticipates commencing a later-stage, multicenter trial of NSI-566 for treatment of ALS in 2015. Neuralstem has received orphan designation by the FDA for NSI-566 in ALS.
Neuralstem, Inc., a biopharmaceutical corporation, focuses on the development and commercialization of treatments for central nervous system disease based on human neural stem cells and the use of small molecule compounds.
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
ACADIA Pharmaceuticals Inc. (ACAD), offered an update on the planned timing of its NUPLAZIDTM (pimavanserin) New Drug Application (NDA) submission.
ACADIA plans to submit its NUPLAZID NDA for the treatment of Parkinson’s disease psychosis in the second half of 2015. The corporation had formerly planned to submit the NDA in the first quarter of 2015. The decision to move back the planned submission is based on additional time required to complete the preparation of systems to support commercial manufacturing and supply and, in turn, to support the U.S. Food and Drug Administration’s (FDA) review of NUPLAZID. The change in submission timing is not a result of any change to NUPLAZID’s clinical or safety profile, nor is it a result of any interaction with or request for information from the FDA.
ACADIA Pharmaceuticals Inc., a biopharmaceutical corporation, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders.
Walter Energy, Inc. (NYSE:WLT)
Formerly on March 5, Walter Energy, Inc. (WLT), declared that the Corporation has been notified by the New York Stock Exchange that its ordinary stock does not presently satisfy one of the NYSE’s continued listing standards. The NYSE requires that the average closing price per share of a listed corporation’s ordinary stock be at least $1.00 over a successive 30 trading-day period. As of March 3, 2015, the average closing price per share of the Corporation’s ordinary stock over the preceding 30 trading-day period was $0.99.
Under the NYSE’s rules, the Corporation has six months to regain compliance with the NYSE’s continued listing standards. The Corporation’s ordinary stock will continue to be listed and traded on the NYSE during this period, subject to the Corporation’s compliance with other continued listing standards. As required by the NYSE’s rules, the Corporation plans to notify the NYSE within 10 business days of the receipt of the notice of non-compliance of its intent to cure the deficiency.
The deficiency does not affect the Corporation’s business operations or its Securities and Exchange Commission reporting requirements, and it does not violate any of the Corporation’s credit contracts or other debt obligations.
Walter Energy, Inc. produces and exports metallurgical coal for the steel industry. It operates through two segments, U.S. Operations, and Canadian and U.K. The Corporation also produces thermal coal, anthracite, metallurgical coke and coal bed methane gas. Walter Energy employs about 2,700 employees, with operations in the United States, Canada and the United Kingdom.
Bovie Medical Corporation (NYSEMKT:BVX)
Bovie Medical Corporation (BVX), a maker of medical devices and supplies and the developer of J-Plasma®, a patented new surgical product, declared that it has priced an underwritten public offering of 4,800,000 shares of its ordinary stock at a price to the public of $2.50 per share. In addition, Bovie has granted the underwriter a 30-day option to purchase up to 720,000 additional shares of ordinary stock to cover over-allotments, if any. The offering is predictable to close on or about March 17, 2015, subject to satisfaction of customary closing conditions.
The total gross proceeds of the offering are predictable to be about $12.0 million. After deducting the underwriter’s discount and other estimated offering expenses payable by Bovie, the net proceeds to the Corporation are predictable to be about $10.6 million. These amounts assume no exercise of the underwriter’s over-allotment option.
Craig-Hallum Capital Group LLC acted as sole managing underwriter for the offering.
Bovie Medical Corporation engages in developing, manufacturing, and marketing a range of electrosurgical products and technologies, in addition to related medical products used in doctor’s offices, surgery centers, and hospitals worldwide.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
